These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012 [Abstract] [Full Text] [Related]
5. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS. Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432 [Abstract] [Full Text] [Related]
9. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial. Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O. Int J Cardiol; 2012 Mar 22; 155(3):418-23. PubMed ID: 21106264 [Abstract] [Full Text] [Related]
10. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C. Alioglu E, Saygi S, Turk U, Kirilmaz B, Tuzun N, Duman C, Tengiz I, Yildiz S, Ercan E. Cardiovasc Ther; 2013 Jun 22; 31(3):168-73. PubMed ID: 22212518 [Abstract] [Full Text] [Related]
11. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results. Chousterman BG, Bouadma L, Moutereau S, Loric S, Alvarez-Gonzalez A, Mekontso-Dessap A, Laissy JP, Rahmouni A, Katsahian S, Brochard L, Schortgen F. J Crit Care; 2013 Oct 22; 28(5):701-9. PubMed ID: 23683568 [Abstract] [Full Text] [Related]
13. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial. Habib M, Hillis A, Hammad A. Saudi J Kidney Dis Transpl; 2016 Jan 22; 27(1):55-61. PubMed ID: 26787567 [Abstract] [Full Text] [Related]
15. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography. Calabrò P, Bianchi R, Caprile M, Sordelli C, Cappelli Bigazzi M, Palmieri R, Gigantino G, Limongelli G, Capozzi G, Cuomo S, Calabrò R. Minerva Cardioangiol; 2010 Feb 22; 58(1):35-40. PubMed ID: 20145594 [Abstract] [Full Text] [Related]
17. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio. Worasuwannarak S, Pornratanarangsi S. J Med Assoc Thai; 2010 Jan 22; 93 Suppl 1():S29-34. PubMed ID: 20364554 [Abstract] [Full Text] [Related]